001     851774
005     20220930130157.0
024 7 _ |a 10.1074/jbc.RA118.003116
|2 doi
024 7 _ |a 0021-9258
|2 ISSN
024 7 _ |a 1083-351X
|2 ISSN
024 7 _ |a 2128/19847
|2 Handle
024 7 _ |a pmid:30131337
|2 pmid
024 7 _ |a WOS:000447256000001
|2 WOS
024 7 _ |a altmetric:49720363
|2 altmetric
037 _ _ |a FZJ-2018-05289
082 _ _ |a 570
100 1 _ |a Rösener, Nadine
|0 P:(DE-Juel1)161275
|b 0
|u fzj
245 _ _ |a A D-enantiomeric peptide interferes with hetero-association of amyloid-β oligomers and prion protein
260 _ _ |a Bethesda, Md.
|c 2018
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1540303232_18558
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. One AD hallmark is the aggregation of amyloid-β (Aβ) into soluble oligomers and insoluble fibrils. Several studies have reported that oligomers rather than fibrils are the most toxic species in AD progression. Aβ oligomers bind with high affinity to membrane-associated prion protein (PrP), leading to toxic signaling across the cell membrane, which makes the Aβ–PrP interaction an attractive therapeutic target. Here, probing this interaction in more detail, we found that both full-length, soluble human (hu) PrP(23–230) and huPrP(23–144), lacking the globular C-terminal domain, bind to Aβ oligomers to form large complexes above the megadalton size range. Following purification by sucrose density–gradient ultracentrifugation, the Aβ and huPrP contents in these hetero-assemblies were quantified by reversed-phase HPLC. The Aβ:PrP molar ratio in these assemblies exhibited some limited variation depending on the molar ratio of the initial mixture. Specifically, a molar ratio of about four Aβ to one huPrP in the presence of an excess of huPrP(23–230) or huPrP(23–144) suggested that four Aβ units are required to form one huPrP-binding site. Of note, an Aβ-binding all-D-enantiomeric peptide, RD2D3, competed with huPrP for Aβ oligomers and interfered with Aβ–PrP hetero-assembly in a concentration-dependent manner. Our results highlight the importance of multivalent epitopes on Aβ oligomers for Aβ–PrP interactions and have yielded an all-D-peptide-based, therapeutically promising agent that competes with PrP for these interactions.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Gremer, Lothar
|0 P:(DE-Juel1)145165
|b 1
|u fzj
700 1 _ |a Reinartz, Elke
|0 P:(DE-HGF)0
|b 2
700 1 _ |a König, Anna
|0 P:(DE-Juel1)165994
|b 3
|u fzj
700 1 _ |a Brener, Oleksandr
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Heise, Henrike
|0 P:(DE-Juel1)132002
|b 5
|u fzj
700 1 _ |a Hoyer, Wolfgang
|0 P:(DE-Juel1)166306
|b 6
|u fzj
700 1 _ |a Neudecker, Philipp
|0 P:(DE-Juel1)144510
|b 7
|u fzj
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 8
|e Corresponding author
|u fzj
773 _ _ |a 10.1074/jbc.RA118.003116
|g p. jbc.RA118.003116 -
|0 PERI:(DE-600)1474604-9
|p jbc.RA118.003116 -
|t The journal of biological chemistry
|v 293
|y 2018
|x 1083-351X
856 4 _ |u https://juser.fz-juelich.de/record/851774/files/2018-09-13_Willbold.pdf
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/851774/files/2018-09-13_Willbold.pdf?subformat=pdfa
856 4 _ |y Published on 2018-08-21. Available in OpenAccess from 2019-08-21.
|u https://juser.fz-juelich.de/record/851774/files/J.%20Biol.%20Chem.-2018-R%C3%B6sener-15748-64-1.pdf
856 4 _ |y Published on 2018-08-21. Available in OpenAccess from 2019-08-21.
|x pdfa
|u https://juser.fz-juelich.de/record/851774/files/J.%20Biol.%20Chem.-2018-R%C3%B6sener-15748-64-1.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:851774
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)161275
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)145165
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)165994
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)132002
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)166306
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)144510
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J BIOL CHEM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 1 _ |a APC
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a APC
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21